November 30, 2022

Execution of an exclusive Research Collaboration Option and Exclusive License Agreement and Equity Investment Agreement with BioNTech SE

Year

2022

Assets in this page

Download assets

  • pdf file

    Current Report ESPI 26/2022

    Download